AB0509 IDENTIFICATION OF NOVEL BIOMARKERS ASSOCIATED WITH DISEASE ACTIVITY OF PRIMARY SJÖGREN'S SYNDROME AND CLINICAL RESPONSE TO VAY736
Background: Overexpression of B cell activating factor (BAFF) contributes to the pathogenesis of primary Sjögren's syndrome (pSS) [1] . Treatment of pSS patients with VAY736, an anti-human BAFF receptor mAb, appears promising and was associated with a positive therapeutic effect [2] . Given the complexity and heterogeneity of pSS, there is a need to further identify molecular mechanisms involved in pSS and in response to new therapeutics. Objectives: To address this question, we assessed a panel of biomarkers in 27 patients from a clinical trial and tested their associations with pSS activity and clinical response to VAY736. Methods: This study comprised 27 pSS patients treated with a single intravenous dose of VAY736 at 10 mg/kg (n=12), 3 mg/kg (n=6), or placebo (n=9). The disease activity scores included EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) and Patient Reported Index (ESSPRI), patient's and physician's reported visual analog scales (VAS), Short-Form 36 and Multidimensional Fatigue Inventory (MFI). BAFF and a panel of chemokines in serum and saliva were assessed using immunoassays. Circulating B cells and B cell subsets were measured by flow cytometry. High frequency ultrasound (US) of the parotid and sub-mandibular glands measured gland thickness and quality using a 4 point scoring (de Vita) [3] . Shear wave elastography of the parotid glands was also measured. All biomarkers were measured at baseline (BL) and post-treatment w6, w12, w24. The effect of VAY736 on biomarker levels was assessed by descriptive statistics. Correlations between biomarkers and disease activity scores were calculated at BL and w6, w12, and w24 using levels and relative changes from BL. Results: In addition to B cell depletion, serum BAFF increase, and improvements in US and elastography measures [2], a subset of serum chemokine tended to be reduced nine weeks after VAY736 treatment. Pooling all 27 patients, salivary BAFF levels correlated with parotid De Vita scores at BL (left: r=0.75, right: r=0.72, p<10 -4 for both) and w6 (left: r=0.72,; right: r=0.78, p<10 -4 for both) but not at later time points. Pooling the 18 VAY736 treated patients, increase in salivary BAFF correlated with decrease in MFI at w6 (r=-0.83, p=3×10
-4 ) and high levels of one of the serum chemokines at BL correlated with decrease in ESSPRI at w24 (r=-0.76, p=3×10 -4 ). In the same patients, the B cell count at BL correlated with changes in several clinical outcomes at w12: ESSPRI (r=-0.65, p=0.01), Physician's VAS (r=-0.6, p=0.01), shear wave (r=-0.63, p=0.02), and parotid thickness (r=-0.6, p=0.03).
Conclusions:
We identified a set of markers correlated with clinical outcomes in pSS after treatment with VAY736, which have the potential to provide additional insight in pSS and treatment-modifying effects. Further large-scale studies are necessary to confirm the value of these markers. Objectives: The aim of the study was to identified and classified the group of NPSLE patients with evaluation of disease activity.
Methods:
We observed clinical neuropsychiatric (NP) manifestations in the cohort of 128 Polish patients with SLE. All patients with suspicion of NP symptoms had neuropsychological and imaging examinations. Symptoms of NPSLE were observed in 38 (30%) patients (34 female and 4 male) with average age 38±6 years (range 18-61 yrs), average disease duration 6,6±5,6 years (range 1,0 -18,0 yrs). Patients were treated with oral and pulse glucocorticoids (GC) and 89% of them standard immunosuppressive drugs (CYC, MMF, AZA,MTX, CsA). As a background therapy 82% of these patients were on chloroquine or hydroksychloroquine (CQ/HCQ). All patients were assessed according to Systemic Lupus Erythematosus Disease Activity Index by SLEDAI (version 2000), Physical Global Assessment (PGA) and damage index (SDI).
Results: Central and peripheral NPSLE symptoms were recognized and categorized (Tab 1). All NPSLE patients had symptoms from central nervous system, but only 16% (n=6) of them had peripheral lupus manifestations. Mean SLEDAI score at NP event was very high 29±9,6, but mean SLEDAI score without NP symptoms was 15±8,3 and was connected with musculoskeletal, mucocutaneous, renal and hematological domains respectively n=29, 76%; n=23, 60%; n=11, 29%; n=8, 21%. Low disease activity was estimated at 3% of patients examined.Most of lupus patients (n=37, 97%) had moderate or high disease activity regardless of NP symptoms. In our study group lupus patients during NPSLE symptoms were immunologically active with increased anti-dsDNA antibodies (n=30, 78%) and/or lower complements C3 and/or C4 levels (n=21, 55%).
Conclusions:
In Polish lupus cohort we observed more frequently lupus-related primary neuropsychiatric symptoms from central nervous system, especially cognitive dysfunctions, mood disorders, cerebrovascular events. Clinical activity of NPSLE patients was rather high and definitely most of patients were immunologically active despite aggressive immunosuppressive treatment and with standard background therapy. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4265
